INTRODUCTION
Acne is a chronic disease which results in significant psychological burden and reduced quality of life for patients [1] . The disease has been ranked as the eighth most prevalent disease worldwide [2] . Prompt and effective treatment is crucial for the prevention of acne sequelae [3] . The current armamentarium for the topical treatment of acne includes an array of agents which can be used in combination [4] . A combination recommended by international guidelines for the topical treatment of acne involves the use of a retinoid, such as adapalene, with benzoyl peroxide (BPO) [4] [5] [6] .
Adapalene possesses comedolytic, anticomedogenic, and anti-inflammatory properties [7] [8] [9] [10] [11] . The efficacy and safety of adapalene 0.1% gel has been demonstrated in clinical studies [10] [11] [12] . Further studies have reported that a higher concentration of the formulation (adapalene 0.3% gel) shows superior efficacy and a similar tolerability profile compared to adapalene 0.1% gel and vehicle [13, 14] .
Clinical data have also demonstrated that adapalene 0.3% gel was safe and effective in the long-term (12 months) treatment of patients with acne [15] . BPO is the antimicrobial agent of choice due to its bactericidal properties against Propionibacterium acnes (P. acnes), and absence of antibiotic resistance [16] [17] [18] [22] . Although it has been demonstrated that the fixed combination can provide superior success in the reduction of acne lesions and an improvement in the clinical condition of patients compared to that of its monads [16] [17] [18] [19] [20] [21] , there are no data on the drug bioavailability and bioequivalence of these agents. In vitro percutaneous absorption studies could be used for the comparison of these treatment regimens [23, 24] .
The objective of these two studies was to determine the effect of different treatment regimens on the percutaneous absorption of adapalene (0.1% and 0.3%) gel and BPO 2.5% gel in ex vivo human skin.
METHODS
In vitro percutaneous absorption studies were conducted using full-thickness human skin from three donors (per study), mounted on polycarbonate membrane inserts of 6-well culture plates. Skin samples of about 2 9 2 cm were cut out from the isolated skin after careful removal of subcutaneous fat. Skin samples were then carefully transferred into six-well plates on a Transwell Ò insert which allows contact of the receptor fluid to the dermal side of the skin sample, while the stratum corneum remains exposed to the air. Glass cylinders of 1 cm • 0.1% A/BPO gel
• BPO 2.5% gel for 10 min followed by adapalene 0.1% gel.
• Adapalene 0.1% gel for 10 min followed by BPO 2.5% gel.
• BPO 2.5% gel for 10 h followed by adapalene 0.1% gel.
• Adapalene 0.1% gel for 10 h followed by BPO 2.5% gel.
The 0.3% A/BPO study included the following treatment regimens:
• 0.3% A/BPO gel • BPO 2.5% gel for 10 min followed by adapalene 0.3% gel.
• Adapalene 0.3% gel for 10 min followed by BPO 2.5% gel.
• BPO 2.5% gel for 10 h followed by adapalene 0.3% gel.
• Adapalene 0.3% gel for 10 h followed by BPO 2.5% gel. Skin samples were incubated (37°C and 5% CO 2 ) for 24 h. Each condition was performed in triplicate for each of the three donors (i.e. n = 9). Concentrations of adapalene and BPO equivalent (BPO-eq) (i.e. benzoic acid after chemical transformation of BPO) were measured using high-performance liquid chromatography.
Comparison between the different treatment regimens was performed using the geometric mean ratio of test/reference treatment approach a (bioequivalence criterion estimated ratio of geometric means between 0.8 and 1.25).
Compliance with Ethics Guidelines
This article does not contain any new studies with human or animal subjects performed by any of the authors.
RESULTS

1% A/BPO Study
Skin Characteristics
Three full-thickness skin samples from three female donors, aged 56-79 years, were used in the study. The skin sample thickness ranged between 1.7 and 2.2 mm.
Adapalene Release Figure 1 illustrates the total penetrated adapalene for 0.1% A/BPO. Based on the bioequivalence acceptance criterion, the results showed that all free-combination regimens were different from 0.1% A/BPO gel, with geometric mean ratios outside the acceptance interval of 80-120% (Fig. 2) . The 0.1% A/BPO gel showed higher adapalene release compared to all monad formulations. Figure 3 illustrates the total penetrated BPO-eq for 0.1% A/BPO. According to the bioequivalence acceptance criterion, the free-combination regimens with application of adapalene 0.1% gel prior to BPO 2.5% gel were different from A/BPO gel treatment (Fig. 4) . The 0.1% A/BPO gel showed higher BPO-eq release compared to monad formulations.
BPO-eq Release
3% A/BPO Study
Skin Characteristics
Three full-thickness skin samples from 2 male and 1 female donors, aged 31-55 years, were used in the study. The skin sample thickness was between 1.6 and 3.2 mm. Based on the bioequivalence acceptance criterion, the results showed that all free-combination regimens were different from 0.3% A/BPO (Fig. 5) . The fixed-combination 0.3% A/BPO gel showed higher adapalene release compared to all free combinations of monad formulations. Figure 3 illustrates the total penetrated BPO-eq for 0.3% A/BPO. The regimen adapalene 0.3% for 10 h followed by BPO 2.5% showed lower BPO-eq release when compared to that observed for 0.3% A/BPO (Fig. 6) . Comparison of the two fixed combinations did not reveal differences in the absorption of BPO-eq between 0.1% A/BPO and 0.3% A/BPO. The total amount of penetrated BPO-eq was not modified in regimens where BPO 2.5% was applied first nor for adapalene 0.3% for 10 min followed by the BPO 2.5% regimen. However, low BPO-eq levels were recovered when adapalene 0.1% was applied first and for adapalene 0.3% followed 10 h later by BPO 2.5%. In these regimens, the geometric mean criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
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